ASCO 25: Merus bispecific scores again in HNSCC
Source
Pharmaphorum
Merus's Petosemtamab Shows 40.4% Response Rate in Head & Neck Cancer Trial
snippet
Merus (MRUS) announced updated clinical data for petosemtamab in treating recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
Source
Stock Titan